Rolvedon-Eflapegrastim
Long-acting G-CSF is standard supportive care in myelosuppressive chemotherapy, a market reshaped by pegfilgrastim biosimilars competing largely on price. Rolvedon (eflapegrastim) entered as a distinct molecule rather than a biosimilar. Its novel Fc-linked construct stimulates the bone marrow to produce neutrophils, shortening the period of severe neutropenia. Injected once per chemotherapy cycle, it decreases infection […]
Sotyktu-Deucravacitinib
Sotyktu (deucravacitinib) sought the efficacy of a JAK inhibitor in psoriasis without inheriting the class-wide safety warnings that limit their use. Deucravacitinib binds a regulatory pseudokinase domain rather than the active site, selectively blocking IL-23 and interferon signaling as the first allosteric TYK2 inhibitor. The once-daily tablet treats adults with moderate-to-severe plaque psoriasis who are […]
Xenpozyme-Olipudase Alfa
Xenpozyme (olipudase alfa) was the first therapy approved for acid sphingomyelinase deficiency, historically called Niemann-Pick disease types A and B, in which sphingomyelin accumulates in the liver, spleen, and lungs. Olipudase alfa replaces the deficient enzyme, breaking down accumulated sphingomyelin to reduce organ enlargement and improve lung function. Infusions are given every two weeks with […]
Amvuttra-Vutrisiran
Hereditary transthyretin amyloidosis progressively damages nerves through misfolded protein deposits, and silencing the source protein proved an effective strategy. Amvuttra (vutrisiran) refined that approach into infrequent dosing. As an RNA interference therapy, it degrades transthyretin messenger RNA in the liver, reducing production of the protein that forms amyloid deposits. The subcutaneous injection is given once […]
Vtama-Tapinarof
Topical psoriasis treatment has depended on corticosteroids and vitamin D analogs, both limited by how long they can safely be used. Vtama (tapinarof) introduced a steroid-free mechanism without those duration limits. It activates the aryl hydrocarbon receptor in skin cells to downregulate IL-17 signaling, normalize barrier protein expression, and reduce oxidative stress. The once-daily cream […]
Mounjaro-Tirzepatide
Mounjaro (tirzepatide) settled a long-running debate about whether adding GIP agonism to GLP-1 would help or hurt in type 2 diabetes. Tirzepatide engages two incretin pathways at once, producing greater HbA1c and weight reduction than GLP-1 agonism alone in head-to-head trials. The once-weekly subcutaneous injection improves glycemic control in adults with type 2 diabetes alongside […]
Voquezna-Vonoprazan, Amoxicillin, And Clarithromycin
Helicobacter pylori eradication rates have fallen as clarithromycin resistance spread, and proton pump inhibitor effect varies with CYP2C19 genotype. Voquezna’s regimens were built around a different acid blocker. Vonoprazan raises gastric pH more rapidly and consistently than proton pump inhibitors, improving antibiotic stability and activity. Co-packaged with amoxicillin and clarithromycin as a 14-day oral regimen, […]
Camzyos-Mavacamten
Hypertrophic cardiomyopathy was long managed with drugs borrowed from other cardiac conditions rather than therapies built for it. Camzyos (mavacamten) changed that as the first cardiac myosin inhibitor approved by the FDA. By reducing excessive actin-myosin cross-bridging in the heart muscle, it eases outflow tract obstruction and improves exercise capacity rather than only relieving symptoms. […]
Vivjoa-Oteseconazole
Recurrent vulvovaginal candidiasis affects a substantial minority of women, and chronic suppressive fluconazole carries resistance and teratogenicity concerns. Vivjoa (oteseconazole) was the first therapy approved specifically for recurrence. Oteseconazole selectively inhibits fungal CYP51 with minimal activity against human CYP enzymes, and its long half-life supports extended dosing. The oral azole reduces the incidence of recurrent […]
Pluvicto-Lutetium (177lu) Vipivotide Tetraxetan
Pluvicto turned an unusually clean target into a therapy: prostate cancer expresses PSMA densely and almost uniquely, making it well suited to delivering radiation systemically. It binds PSMA on tumor cells and delivers beta-emitting lutetium-177 directly to them, largely sparing healthy tissue. Given intravenously every six weeks, it treats adults with PSMA-positive metastatic castration-resistant prostate […]
